These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 24771277)
1. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277 [TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
3. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts. Holmberg LA; Linenberger M; Connelly-Smith L Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104 [TBL] [Abstract][Full Text] [Related]
4. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037 [TBL] [Abstract][Full Text] [Related]
5. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584 [TBL] [Abstract][Full Text] [Related]
6. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization. Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786 [TBL] [Abstract][Full Text] [Related]
8. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
9. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928 [TBL] [Abstract][Full Text] [Related]
10. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892 [TBL] [Abstract][Full Text] [Related]
12. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation. Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell]. Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693 [TBL] [Abstract][Full Text] [Related]
15. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497 [TBL] [Abstract][Full Text] [Related]
16. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435 [TBL] [Abstract][Full Text] [Related]
17. Cost analysis of a randomized stem cell mobilization study in multiple myeloma. Varmavuo V; Silvennoinen R; Anttila P; Säily M; Sankelo M; Putkonen M; Ahonen J; Mahlamäki E; Mäntymaa P; Savolainen ER; Remes K; Jantunen E Ann Hematol; 2016 Oct; 95(10):1653-9. PubMed ID: 27485453 [TBL] [Abstract][Full Text] [Related]
18. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]